15 domestic pharmaceutical companies which have challenged to the use patent of Crestor received the ‘declaration of inadmissibility’

Domestic pharmaceutical companies which have challenged to the use patent of ‘Crestor’ received the declaration of inadmissibility.

When it comes to the nullity suit filed by 15 domestic pharmaceutical companies against the use patent of the AstraZeneca’s ‘Crestor(generic name: rosuvastatin)’ expiring in November 2021, the Intellectual Property Tribunal has recently declared inadmissibility. W...